# Linaclotide

Canonical source: https://retacompare.com/encyclopedia/linaclotide

Guanylate cyclase-C agonist on intestinal epithelium; elevates intracellular cGMP, opening CFTR and increasing chloride / fluid secretion into the gut lumen.

Reference facts

Also known asLinzess, ConstellaCategoryGastrointestinalMechanism of actionGuanylate cyclase-C agonist on intestinal epithelium; elevates intracellular cGMP, opening CFTR and increasing chloride / fluid secretion into the gut lumen.TargetsGC-C receptorIndications under research or approvedChronic idiopathic constipation, IBS-C, Functional constipation in pediatricsRegulatory status (reference entry)FDA-approved (2012)Half-lifeNegligible systemic absorptionSequenceCCEYCCNPACTGCYSequence notes14-residue cyclic peptide with three disulfide bonds; oral, gut-restricted.Molecular weight (Da)1527Originator / sponsorIronwood / AbbVieFirst reported2008
    Primary References

Linzess FDA label


    Explore research articles about Linaclotide


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- Linzess FDA label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202811s011lbl.pdf